PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

被引：0
作者：
Liu, S. -Y. M. [1 ,2 ]
Deng, J. -Y. [3 ]
Yan, H. -H. [3 ]
Yang, M. -Y. [3 ]
Xu, C. -R. [3 ]
Zheng, M. -Y. [3 ]
Gan, B. [3 ]
Zhang, X. -C. [3 ]
Tu, H. -Y. [3 ]
Yang, J. -J. [3 ]
Chen, H. -J. [3 ]
Wang, B. -C. [3 ]
Li, Y. [1 ,4 ]
Zhou, Q. [2 ,3 ]
Wu, Y. -L. [2 ,3 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
[2] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[3] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
non-small cell lung cancer; pembrolizumab; sintilimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
WS02.13
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [31] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [32] The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
    Lin, Shen
    Li, Yiyuan
    Gu, Dian
    Luo, Shaohong
    Huang, Xiaoting
    Dong, Liangliang
    Xu, Xiongwei
    Lin, Peili
    Weng, Xiuhua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
    Gauvin, Camille
    Krishnan, Vimal
    Kaci, Imane
    Danh Tran-Thanh
    Bedard, Karine
    Albadine, Roula
    Leduc, Charles
    Gaboury, Louis
    Blais, Normand
    Tehfe, Mustapha
    Routy, Bertrand
    Florescu, Marie
    CURRENT ONCOLOGY, 2021, 28 (01) : 593 - 605
  • [34] Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Gon, Yasuhiro
    Takahashi, Toshiaki
    LUNG CANCER, 2021, 151 : 60 - 68
  • [35] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [36] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [37] Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
    Tsai, Jeng-Shiuan
    Wei, Sheng-Huan
    Chen, Chian-Wei
    Yang, Szu-Chun
    Tseng, Yau-Lin
    Su, Po-Lan
    Lin, Chien-Chung
    Su, Wu-Chou
    PHARMACEUTICALS, 2022, 15 (11)
  • [38] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [39] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
    Abdel-Rahman, Omar
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 : 75 - 85
  • [40] Pembrolizumab plus Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis
    Ang, K. F.
    Villafuerte, R. J.
    Regala, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1070 - S1071
12345